According to a phase 1 trial, the experimental HIVconsvX vaccine is safe and immunogenic among sub-Saharan African ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

The approach employed by the research team could be used against other diseases—including COVID-19 and influenza.

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

Researchers at MIT and the Scripps Research Institute have shown that they can generate a strong immune response to HIV with ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

Researchers have shown that a tiny nanoparticle formulation of saponin, along with an inflammation-promoting molecule called ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

By C.J. Atkins Just in time for Pride month, President Donald Trump and Health Secretary Robert F. Kennedy, Jr., have ...